NEW YORK, April 3, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today the appointment of Dr. Adel Nada as Vice President, Immunotherapy. In this position, Dr. Nada will be responsible for developing the Company's T Regulatory Cell Program, which is investigating the use of T Regulatory Cells ("Tregs") to treat diseases caused by imbalances in the immune system. The Company plans to initiate a Phase 2 study of Treg based therapeutics to treat type 1 diabetes in the third quarter of 2014, as well as a Phase 1 study in Canada of Treg based therapeutics in support of a steroid resistant asthma indication in 2014.
NeoStem Welcomes Dr. Adel Nada As Vice President, Immunotherapy
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.